Leadership

Our executive team
Neal A. Patel

Chief Executive Officer

Under his leadership, Elixia’s total enterprise value has more than quadrupled, the number of employees tripled and the company has received numerous accolades for its work across several therapeutic focuses.

Jim F. Crissy

Chief Operating Officer

In his role of COO for Elixia, Jim provides strategic direction and operational oversight to a diverse and unique system of logistics that reflects the disruptive nature of Elixia’s forward approach to clinical trials.

Sam Searcy

Chief Commercial Officer

Sam is an industry veteran who brings access to a professional network of the top CROs and pharma companies. Elixia’s disruptive model is fueled by his expertise in aligning therapeutic knowledge to client needs.

Harry Alcorn

Chief Scientific Officer

Harry masterfully orchestrates the fusion of operational strategy and scientific innovation with deep-rooted industry expertise. His command of our Early Phase Clinical Trials Division underpins Elixia’s leadership in niche-focused clinical trials.

Jennifer L. Yevoli

General Counsel

As General Counsel, Jennifer advises Elixia on a wide range of corporate, regulatory, contracting, and business issues and heads compliance and corporate integrity efforts across the organization.

Management Team
Sahil Mehta

VP of Strategic Operations

Dalia Vrooman

Director of Patient Engagement and Inclusion

Dolly Rivera

VP of Site Network Advancement

Isabel Castano

Head of Quality Assurance Division

UNCONVENTIONAL. RESTLESS. DISRUPTIVE.

“When we talk about ‘disruption,’ we mean replacing the traditional model with a new gold standard for operational processes, patient recruitment, site management, and all the things that have forever plagued pharma. We are redefining expectations about what is possible in clinical development in terms of speed, reliability, scalability and reproducibility. Elixia does only a few things and we do them really well. We have to, because what’s on the line for our clients is missing timelines, a lack of diversity, or even failed trials. Clients and patients deserve more.”

null

Neal Patel

CEO